Ireland - English - HPRA (Health Products Regulatory Authority)

elanco gmbh - benazepril hydochloride - tablet - 2.5 milligram(s) - benazepril

United Kingdom - English - VMD (Veterinary Medicines Directorate)

elanco europe ltd - benazepril hydrochloride - tablet - cardio vascular ace inhibitor - cats, dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

elanco europe ltd - benazepril hydrochloride - tablet - cardio vascular ace inhibitor - cats, dogs

United Kingdom - English - VMD (Veterinary Medicines Directorate)

elanco europe ltd - benazepril hydrochloride - tablet - cardio vascular ace inhibitor - dogs

Australia - English - Department of Health (Therapeutic Goods Administration)

sklarexen pty ltd - butyl methoxydibenzoylmethane,homosalate,octocrylene,octyl salicylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sklarexen pty ltd - butyl methoxydibenzoylmethane,homosalate,octocrylene,octyl salicylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sklarexen pty ltd - butyl methoxydibenzoylmethane,homosalate,octocrylene,octyl salicylate -

European Union - English - EMA (European Medicines Agency)

bayer ag - riociguat - hypertension, pulmonary - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah) adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.